T 1399/04 (Combination therapy HCV/SCHERING) of 25.10.2006

European Case Law Identifier: ECLI:EP:BA:2006:T139904.20061025
Date of decision: 25 October 2006
Case number: T 1399/04
Application number: 99303729.0
IPC class: A61K 38/21
Language of proceedings: EN
Distribution: C
Download and more information:
Decision text in EN (PDF, 63 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
Applicant name: SCHERING CORPORATION
Opponent name: 01. Alfa Wassermann S.p.A.
02. Teva Pharmaceutical Industries Ltd.
03. Sandoz GmbH
04. Krauss, Jan B.
Board: 3.3.04
Headnote: -
Relevant legal provisions:
European Patent Convention 1973 Art 52(4)
European Patent Convention 1973 Art 54
European Patent Convention 1973 Art 87
European Patent Convention 1973 Art 88
European Patent Convention 1973 Art 89
European Patent Convention 1973 Art 111(1)
European Patent Convention 1973 Art 113(1)
European Patent Convention 1973 Art 123(2)
European Patent Convention 1973 R 67
Keywords: Substantial procedural violation - (yes)
Reimbursement of the appeal fee - (yes)
Admissibility of late-filed documents - (yes)
Added subject-matter - (no)
Not patentable invention - (no)
Priority, novelty - (yes)
Catchwords:

-

Cited decisions:
G 0005/83
G 0004/92
G 0002/98
T 0019/86
T 0081/87
T 0133/87
T 0893/90
T 0125/91
T 0464/94
T 0808/94
T 0233/96
T 0914/98
T 1020/03
Citing decisions:
T 1545/08
T 0734/12
T 1508/13
T 2474/13
T 1044/14
T 0694/16

Source: http://www.epo.org/law-practice/case-law-appeals/recent/t041399eu1.html

Date retrieved: 17 May 2021

17 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

Case Law Book: I Patentability

Case Law Book: V Priority

Case Law of the Enlarged Board

General Case Law